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Abstract
Background: Guillain–Barré syndrome (GBS) is an acute, post-infectious, immune-mediated, demyelinating disease
of peripheral nerves and nerve roots. Dimethyl fumarate (DMF), a fumaric acid ester, exhibits various biological
activities, including multiple immunomodulatory and neuroprotective effects. However, the potential mechanism
underlying the effect of DMF in GBS animal model experimental autoimmune neuritis (EAN) is unclear.
Methods: Using EAN, an established GBS model, we investigated the effect of DMF by assessing clinical score,
histological staining and electrophysiological studies. Then, we further explored the potential mechanism by
Western blot analysis, flow cytometry, fluorescence immunohistochemistry, PCR, and ELISA analysis. The Mann–
Whitney U test was used to compare differences between control group and treatment groups where appropriate.
Results: DMF treatment reduced the neurological deficits by ameliorating inflammatory cell infiltration and
demyelination of sciatic nerves. In addition, DMF treatment decreased the level of pro-inflammatory M1
macrophages while increasing the number of anti-inflammatory M2 macrophages in the spleens and sciatic nerves
of EAN rats. In RAW 264.7, a shift in macrophage polarization from M1 to M2 phenotype was demonstrated to be
depended on DMF application. In sciatic nerves, DMF treatment elevated the level of the antioxidant transcription
factor nuclear factor erythroid-derived 2-related factor 2 (Nrf2) and its target gene hemoxygenase-1 (HO-1) which
could facilitate macrophage polarization toward M2 type. Moreover, DMF improved the inflammatory milieu in
spleens of EAN rats, characterized by downregulation of messenger RNA (mRNA) of IFN-γ, TNF-α, IL-6, and IL-17 and
upregulation of mRNA level of IL-4 and IL-10.
Conclusions: Taken together, our data demonstrate that DMF can effectively suppress EAN, and the mechanism
involves altering the balance of M1/M2 macrophages and attenuating inflammation.
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Background
Guillain–Barré syndrome (GBS), known as an acute in-
flammatory disorder in the peripheral nervous system
(PNS), can cause rapidly progressive, symmetrical weak-
ness of the extremities [1]. Proven effective immunother-
apies for GBS are plasma exchange and intravenous
treatment with immunoglobulin G [1]. Of note, approxi-
mately 5 % of GBS patients die and up to 20 % suffer
from severe disability, irrespective of whether they re-
ceive immunotherapies [2]. Hence, further researches
are imperative to improve this situation.
Experimental autoimmune neuritis (EAN), a well-
known animal model of GBS, effectively mimics clinical,
histopathological, and electrophysiological features of
GBS. EAN is characterized pathologically by a break-
down of the blood-nerve barrier, robust accumulation of
reactive T cells and macrophages into the PNS, and de-
myelination of peripheral nerves [3]. Pro-inflammatory
cytokines including IL-6, IFN-γ, IL-17, and TNF-α,
mostly secreted by Th1 and Th17 cells, predominate in
sciatic nerves and lymphoid organs during the acute
phase of GBS and contribute to inflammatory impair-
ment of peripheral nerves, whereas anti-inflammatory
cytokines such as IL-4 and IL-10, mainly secreted by
Th2 cells, are proven beneficial for the protection of in-
flammatory impairment of peripheral nerves [4, 5].
The polarized macrophages are generally termed pro-
inflammatory M1 or classically activated macrophages
and anti-inflammatory M2 or alternatively activated mac-
rophages [6, 7]. M1 macrophages, which arise mainly in
response to IFN-γ [8], are involved in the pathogenesis
and course of EAN through their antibody-dependent cel-
lular cytotoxicity (ADCC) and phagocytosis and myelin
sheath damage [9]. M2 phenotype macrophages which
arise mainly in response to IL-4 [8], however, contribute
to recovery by promoting T-cell apoptosis and the secre-
tion of anti-inflammatory cytokines [10], promoting mye-
lin repair and axonal regeneration [11]. Evidence shows
that a switch in macrophage phenotype from M1 to M2
could influence the pathogenesis of autoimmune and in-
flammatory diseases [12]. We hypothesize that treatment
facilitating the switch of macrophage phenotype from M1
to M2 may favor the outcome of EAN.
Dimethyl fumarate (DMF), an orally bioavailable fu-
maric acid ester, has been used successfully as a drug for
treating the autoimmune disorders such as psoriasis
since the 1990s [13] and relapsing/remitting multiple
sclerosis (MS) since 2013 [14]. Recent report shows that
it can ameliorate EAN as well [15], but the exact mecha-
nisms underlying its effect is still unclear. In addition,
previous studies demonstrate that DMF ameliorates MS
by reducing inflammation [16, 17] and enhancing activa-
tion of the nuclear factor erythroid-derived 2-related
factor 2 (Nrf2) antioxidant pathway [18]. As a basic
leucine-zipper (bZip) transcription factor, Nrf2 protects
a variety of tissues and cells against oxidative, inflamma-
tory, and electrophilic stress through antioxidant re-
sponse element (ARE)-mediated induction of diverse
phase II detoxification and antioxidant enzymes, includ-
ing NAD(P)H quinone oxidoreductase 1 (NQO1) and
hemoxygenase-1 (HO-1) [19, 20]. As the major anti-
inflammatory and anti-oxidative enzyme that is regu-
lated by activating Nrf2 [21], HO-1 induction has been
reported to affect macrophage polarization toward M2
phenotype in experimental animal models of diabetes,
Crohn’s disease, hypertension, alcoholic liver disease,
and intestinal injury [22]. Herein, we hypothesized that
HO-1 induction by DMF may exert a protection against
EAN.
The objective of this study was to assess the effect of
DMF in treating EAN and the underlying mechanisms.
DMF was applied in a preventative and a therapeutic
paradigm, and the effect on clinical, histological, and im-
munological parameters was assessed. It is demonstrated
that DMF is effective in treating EAN and the mechan-
ism of action involves mobilization of anti-inflammatory
and immunomodulatory responses mediated by the
Nrf2/HO-1 pathway.
Methods
Experimental animals and group assignments
Male Lewis rats, 6–8 weeks old (160–190 g), were pur-
chased from the Vital River Corporation (Beijing, China).
All animals were acclimated to the vivarium environment
and were maintained under temperature-controlled condi-
tions and a 12-h light/dark cycle for 1 week. Food and
water were provided ad libitum. Animals were randomly
assigned to three groups (preventative, therapeutic, or
control, n = 6 per group) and each group was repeated 3
times. All efforts were made to minimize the number of
animals used and any suffering they might experience.
The experimental procedures were approved by the Ani-
mal Ethics Committee of the Tianjin Medical University.
Induction and clinical evaluation of EAN
EAN was induced by injecting both hind footpads with
300 μl of an inoculum containing 300 μg of dissolved P0
peptide 180-199 (10 mg/ml; Bio-Synthesis Corporation).
The peptide was dissolved in phosphate-buffered saline
(PBS) (2 mg/ml) and then emulsified with an equal vol-
ume of complete Freund’s adjuvant (CFA; Difco) con-
taining Mycobacterium tuberculosis (strain H37RA) to a
final concentration of 1 mg/ml. Following immunization,
clinical signs of EAN were scored and quantified as fol-
lows: 0 = normal; 1 = reduced tonus of the tail; 2 = limp
tail; 3 = absent righting reflex; 4 = gait ataxia; 5 =mild
paresis of the hind limbs; 6 = moderate paraparesis; 7 =
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severe paraparesis or paraplegia of the hind limbs; 8 =
tetraparesis; 9 =moribund; and 10 = death.
DMF treatment
Dimethyl fumarate (DMF; 97 % pure) (Sigma-Aldrich)
was freshly prepared in 0.08 % carboxymethyl cellulose
(CMC)/PBS. For preventative treatment, DMF solution
was administered by oral gavage (25 mg/kg body weight/
day) from day 1 to day 16 post-immunization (i.e., peak
phase) or day 27 post-immunization (i.e., remission
phase). For therapeutic treatment, DMF solution was ad-
ministered by oral gavage at the same dose daily from
the day on which the first clinical signs were observed,
namely from day 7 to day 16 or 27 post-immunization.
Control animals received the same volume of the vehicle
solution (i.e., 0.08 % CMC/PBS). The dose of DMF was
based on previously published studies [23, 24] and on
preliminary studies done in our laboratory.
Electrophysiological studies
Electromyographic (EMG) recordings of the left sciatic
nerve were made on day 16 post-immunization (i.e.,
peak phase) using a fully digital Keypoint Compact
EMG/NCS/EP recording system (Dantec Co). A single
blind trial method was used to record evoked compound
muscle action potential (CMAP) amplitudes and laten-
cies of sciatic nerves, as previously described [25]. Rats
were anesthetized first with chloral hydrate (intraperito-
neally, 3 mg/kg). Two pairs of monopolar needle elec-
trodes were used to stimulate the sciatic nerve and
record the signals, respectively. After exposing the left
sciatic nerve from the hip (proximal) to the ankle (dis-
tal), one pair of needle electrodes was inserted at the sci-
atic notch (hip/proximal) or the ankle (ankle/distal). The
nerve stimulation parameters used to elicit CMAPs were
1-Hz pulses, with each pulse being 5 mA in amplitude
and 0.3 ms in duration. The recording electrodes were
positioned in the “belly” part of the gastrocnemius
muscle to record evoked potentials from stimulating the
sciatic nerve. The motor nerve conduction velocity
(MNCV) was calculated by measuring the distance be-
tween stimulating cathode electrodes and then measur-
ing the latency difference. The amplitude was calculated
from the baseline to the maximal peak under the result-
ing CMAP curves. After electrophysiologic measure-
ments were completed, the incision was sutured under
an aseptic environment. Body temperatures of rats dur-
ing electrophysiologic measurements were maintained
above 34 °C by positioning a heating pad under the rat.
For each animal, triplicate measurements were made.
Histopathological assessment
Following nerve conduction studies, the sciatic nerves of
each rat were harvested at the peak of disease (day 16 post-
immunization). Six rats from each group received general
anesthesia and were then perfused intracardially, first with
4 °C PBS for 2 min, followed by 4 % paraformaldehyde dis-
solved in PBS for 5 min. The sciatic nerves were rapidly
removed and fixed in 4 % paraformaldehyde overnight
at 4 °C, and then the nerves were embedded in paraffin.
To evaluate the extent of mononuclear cell (MNC) infil-
tration and demyelination, serial transverse sections (6 μm)
were stained with hematoxylin-eosin (H&E) (Solarbio Sci-
ence & Technology) and luxol fast blue (LFB), which
contains 0.1 % LFB solution, 0.1 % Cresyl Echt Violet solu-
tion, and 0.05 % lithium carbonate solution. Infiltrating in-
flammatory cells in H&E-stained tissues were counted by
image analysis using a Nikon Coolscope digital microscope
(Nikon). Cell numbers were calculated per square milli-
meter from five random microscopic fields (200× magnifi-
cation). All counts were performed in a blinded fashion.
The average results were expressed as cells per square
millimeter of tissue section. To evaluate the severity of
demyelination, histological scores were calculated. Sections
containing all perivascular areas were assessed by two inde-
pendent observers (who were blinded to the treatment)
according to the following semi-quantitative pathological/
histological scale: 0, normal perivascular area; 1, mild
cellular infiltrate adjacent to the vessel; 2, cellular infil-
tration plus demyelination in immediate proximity to
the vessel; 3, cellular infiltration and demyelination
throughout the section.
Fluorescence immunohistochemistry
Following nerve conduction studies, the sciatic nerves
were harvested at the peak of disease (i.e., day 16 post-
immunization) as described above and post-fixed in 4 %
paraformaldehyde overnight. The nerves were dehy-
drated sequentially in 15 % and then 30 % sucrose until
the tissue equilibrated. After that, nerves were embedded
in Tissue-tek medium (SAKURA) and snap-frozen in li-
quid nitrogen to expose antigenic sites for staining.
Transverse sections (8 μm) were made on a cryostat
(Leica Microsystems LM3050S) and then mounted on
poly-L-lysine-coated slides and stored at −80 °C.
Fluorescence immunohistochemistry of the frozen sec-
tions was performed using standard protocols provided
by the antibody manufacturers. Briefly, after bringing the
slides to room temperature for 20 min, the mounted
tissue was fixed in 4 % paraformaldehyde for 10 min and
permeabilized in 0.3 % Triton X100 for 5 min. Sections
were washed in cold PBS after each step. After blocking
with 3 % BSA for 30 min at 37 °C, slides were incubated
with primary antibodies: rabbit anti-Nrf2 (1:200, Abcam);
rabbit anti-HO-1 (1:200, Abcam); mouse anti-CD68 (1:200,
Abcam); goat anti-Iba1 (1:500, Abcam); rabbit anti-Iba1
(1:500, Wako); rabbit anti-iNOS (1:200, Abcam); rabbit-
CD86 (1:200, Abcam); goat anti-Arginase-1 (1:200, Santa
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Cruz Biotechnology, Inc); and goat anti-CD206 (1:200,
Santa Cruz Biotechnology, Inc) at 4 °C overnight. The next
day, they were washed in PBS and then incubated for
60 min at room temperature with the following species-
appropriate fluorochrome-conjugated secondary anti-
bodies: Rhodamine (TRITC) AffiniPure donkey anti-goat
IgG (H+ L) (1:100, Jackson Immunoresearch); Rhodamine
(TRITC)-conjugated AffiniPure goat anti-rabbit IgG (H +
L) (1:100, Jackson, Immunoresearch); Rhodamine (TRITC)-
conjugated AffiniPure goat anti-mouse IgG (H+ L) (1:100,
Jackson, Immunoresearch); Alexa Fluor® 488 conjugated
donkey anti-rabbit IgG (H + L) (1:1000, Thermo Fisher
Scientific); and Alexa Fluor® 488 conjugated donkey anti-
goat IgG (H + L) (1:1000, Thermo Fisher Scientific). Finally,
the slides were washed in PBS, and the tissue was cover-
slipped with fluoro-shield mounting medium containing
DAPI (Abcam) to counterstain cell nuclei. Image analysis
of stained cells of the entire area of each tissue section
per sciatic nerve was performed using a Nikon Cool-
scope (Nikon). Positive cell numbers were calculated
per square millimeter from three random microscopic
fields (200× magnification). All counts were performed
in a blinded fashion.
Flow cytometry
The polarization state of macrophages derived from rat
spleens was determined at the peak of disease (i.e., day 16
post-immunization) by flow cytometric analysis. In brief,
spleens were removed under aseptic conditions and sple-
nocytes were harvested. For extracellular staining, 1 × 106
spleen MNCs were resuspended in 100 μl PBS/1 % BSA
and were co-stained for cell surface CD11b conjugated
with phycoerythrin (1:100, Abcam), Ly6G conjugated with
FITC (1:100, Abcam) and/or CD206 (1:100, Abcam) for
45 min at room temperature (RT) following manufac-
turer’s specification. For intracellular staining, cells were
first stained with CD11b and Ly6G as above, then fixed
with Fixation Buffer (BioLegend), permeabilized with
Permeabilization Wash Buffer (BioLegend), and then
stained with a primary antibody for intracellular iNOS
(1:100, Abcam) and Alexa Fluor®647-labelled donkey anti-
rabbit IgG (H&L) secondary antibody (1:100, Abcam).
MNCs were gated by forward and sideward scatter. Sur-
face and intracellular molecule expression were assessed
by determining the positive cell percentage. Cells from all
groups were collected and analyzed at each time point
on the same day with the same cytometer settings. Flow
cytometric data were acquired using a FACSAria™ flow
cytometer (BD Biosciences) and analyzed with FlowJo
software version 7.6.1 (flowjo.com).
Western blot analysis
After removal, part of the sciatic nerves were immediately
stored in liquid nitrogen until needed for protein isolation
by TRIzol (Ambion). All procedures were performed fol-
lowing manufacturer’s introduction for obtaining total pro-
tein. After boiling, samples were adjusted to equal content
and volume before being loaded on 10 % SDS-PAGE gels
and electrophoretically separated. Proteins were then
transferred to PVDF membranes (Millipore) followed
by blocking. Proteins were visualized by using primary
antibodies for Nrf2 (1:1000, Abcam) and HO-1 (1:2000,
Abcam), actin (1:1000, Zhongshanjinqiao), and then by
incubating with goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody (1:5000, TRANSGENE
BIOTECH) and goat anti-mouse secondary antibody
(1:5000, TRANSGENE BIOTECH). The protein-specific
signals were detected using a Bio-Rad 721BR08844 Gel
Doc Imager (Bio-Rad).
Lymphocyte proliferation assay
Antigen-specific lymphocyte proliferation was measured by
MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays on day 16
post-immunization as described previously [26]. Briefly,
spleens were removed under aseptic conditions and spleno-
cytes were harvested. Single-cell suspensions of MNCs at a
density of 2 × 106 cells/ml were allocated with 100-μl cul-
ture medium into 96-well microtiter plates. The culture
medium was RPMI1640 (containing 2.05 mM glutamine;
HyClone) supplemented with 1 % (v/v) HEPES buffer solu-
tion (Gibco), 0.1 % (v/v) 2-mercaptoethanol (Gibco), 1 %
(v/v) sodium pyruvate (Gibco), and 1 % (v/v) Pen Strep
(Gibco), and 10 % (v/v) fetal bovine serum (FBS; Gibco).
MNCs were cultured in the presence of either P0 peptide
180–199 (10 μg/ml; Bio-Synthesis Corporation) or without
antigen. The concentration of the peptide used was based
on previous studies [26, 27]. Following incubation for 72 h
at 37 °C and 5 % CO2, MTS solution (Promega) was added
and cells were incubated for an additional 4 h. The absorb-
ance was measured at 490 nm using a microtiter plate
reader (Titertek). Since we administered the drug in vivo,
we could not calculate an inhibitory rate. The data are pre-
sented as mean OD± SEM. The experiment was performed
with MNCs from four different rats in each group, and
MNCs from each rat were done in triplicate.
Real-time quantitative polymerase chain reaction (RT-PCR)
Spleens were removed under aseptic conditions and
splenocytes were harvested as described above. 107 splenic
cells were stored for proceduring RNA isolation by TRIzol
(Ambion). All actions were performanced following
instruction book to get total RNA (10 μg/sample). Total
RNA was reverse transcribed into complementary DNA
(cDNA) using TransScript First-Strand cDNA Synthesis
SuperMix (TRANSGEN BIOTECH). All the procedures
were strictly performed as per instructions. The
primers used to measure gene expression are the following:
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IFN-γ (sense, TCGCACCTGATCACTAACTTCTTC; anti-
sense, CGACTCCTTTTCCGCTTCC), TNF-α (sense, TGA
TCG GTC CCA ACA AGG A; antisense, TGC TTG GTG
GTT TGC TAC GA), IL-4 (sense, TGA TGG GTC TCA
GCC CCC ACC TTG C; antisense, CTT TCA GTG TTG




actin (sense, CCGTCTTCCCCTCCATCGT; antisense, AT
CGTCCCAGTTGGTTACAATGC). The PCR program was
run at 95 °C for 10 min then 40 cycles at 95 °C for 15 s and
60 °C for 1 min. The results were automatically analyzed by
the ABI Stepone Plus instrument, and the method of 2–△△Ct
(△Ct represents the difference of threshold cycle value
between the target gene and the inner control; △△Ct rep-
resents the difference of △Ct between different groups)
was used to analyze the messenger RNAs (mRNA) expres-
sion. Results were calculated as levels of target mRNAs
relative to β-actin (four samples from each group were
analyzed by PCR).
ELISA for cytokine profile
The supernatants of splenic MNCs (2 × 106 cells/ml)
cultured with P0 peptide 180-199 (10 μg/ml)were col-
lected after incubation for 72 h at 37 °C and 5 % CO2.
Simultaneous quantitative analysis of six cytokines, in-
cluding IL-1α, IL-4, IL-6, IL-10, IFN-γ, TNF-α, was per-
formed using a multi-analyte ELISArray Kit (QIAGEN)
according to the manufacturer’s instructions. Determina-
tions were performed in triple, and results are expressed
as mean OD ± SEM (n = 4).
In vitro cell culture
To further investigate the effects of DMF on macrophage
polarization, we used immortalized murine macrophage
cell line RAW 264.7 in vitro. RAW 264.7 cells were grown
in complete RPMI 1640 medium (Life Technologies) con-
taining penicillin (100 U/ml), streptomycin (100 U/ml),
and 10 % FBS (Gibco), maintained at 37 °C and 5 % CO2.
Briefly, 2 × 105 cells were seeded into 24-well cell culture
plates, triplicated either on coverslips pretreated with
polylysine or not, and cultured for 24 h. Then, cells were
stimulated with LPS (Sigma-Aldrich) for 24 h, and after-
wards DMF (0, 20, 50, 100 μM) was added and incubated
for another 24 h. Thereafter, cells on slides were prepared
for immunocytochemistry staining and the other cultured
cells were harvested and centrifuged for RNA analyses
(see below). The staining procedure of cells was similar to
that of the tissue slides as mentioned above. Immunocyto-
chemistry of macrophages on the slides used the following
primary antibodies. To detect M1 macrophage markers,
we used rabbit antibody to iNOS (1:200, Abcam). To de-
tect M2 markers, we used goat antibody to Arginase-1
(1:200, Santa Cruz Biotechnology, Inc). Antibodies used to
mark pan macrophage markers included mouse antibody
to goat anti-Iba1 (1:500, Abcam); rabbit anti-Iba1 (1:500,
Wako). Species-appropriate fluorochrome-conjugated sec-
ondary antibodies were added. Cells were observed by
using fluorescence microscopy (Nikon). Five different fields
of each slide were acquired; the pictures of each group
were collected from triple-cultured cells. Fluorescence in-
tensity of iNOS and Arginase-1 (Arg1) was analyzed semi-
quantitatively by image analysis software (Image ProPlus
6.0 Software). Results were provided as relative intensity
comparing DMF-treated cells to PBS-treated cells.
Total RNA from cultured cells was prepared as de-
scribed above according to the manufacturer’s instruc-
tions. Total RNA was reverse transcribed into cDNA
using TransScript First-Strand cDNA Synthesis Super-
Mix (TRANSGEN BIOTECH). The mRNA expression
levels were measured by real-time PCR using the following
primers: β-actin (sense, TGG AAT CCT GTG GCA TCC
ATG AAA; antisense, TAA AAC GCA GCT CAG TAA
CAG TCC G); TNF-α (sense, AAC TAG TGG TGC CAG
CCG AT; antisense, CTT CAC AGA GCA ATG ACT
CC); iNOS (sense, CAG CTG GGC TGTACA AAC CTT;
antisense, CAT TGG AAG TGA AGC GTT TCG); Arg 1
(sense, TTA GGC CAA GGT GCT TGC TGC C; antisense,
TAC CAT GGC CCT GAG GAG GTT C); and IL-10
(sense, TCA TTC ATG GCC TTG TAG ACA C; antisense,
AGC TGG ACA ACA TAC TGC TAA C). The PCR pro-
gram was run at 95 °C for 10 min, then 40 cycles at 95 °C
for 15 s, and finally at 60 °C for 1 min. The results were
automatically analyzed by an ABI SteponePlus instrument,
and the method of 2–△△Ct was used to analyze mRNA ex-
pression. Results were calculated as levels of target mRNAs
relative to those from untreated RAW 264.7 cells. Four
samples from each group were analyzed by PCR.
Evaluation and statistical analysis
The Mann–Whitney U test was used to compare differ-
ences between control group and treatment groups where
appropriate (GraphPad Prism 5.0). Data are presented as
means ± SEM. For all statistical analyses, the level of sig-
nificance was set at p < 0.05.
Results
DMF treatment attenuates clinical severity, histological
changes, and inflammatory cell accumulation in EAN
Treatment of EAN in our rat model with DMF was inves-
tigated in two different paradigms (Fig. 1). In the pre-
ventative paradigm (blue line), we administered vehicle or
DMF (25 mg/kg/day) by gavage after immunization. In
the therapeutic paradigm (red line), the treatment was
started when the first clinical symptoms occurred on day
7 post-immunization. The severity of EAN was reduced in
both the preventative and therapeutic treatment groups
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compared to the control group (CMC), as measured by
clinical severity scores. The rats in the preventative treat-
ment group exhibited significantly better clinical scores
from day 6 to day 27 compared with the rats in CMC
group (p < 0.05 on each time point). By contrast, clinical
improvement of rats in the therapeutic group was delayed,
with their clinical scores being lower than that of the rats
in CMC group from day 8 to day 27 and the difference
was significant only from day 10 to day 27 (p < 0.05 on
each time point). In addition, the mean peak clinical
score was 5.20 ± 0.30, 5.67 ± 0.25, and 7.42 ± 0.15 in the
preventative, therapeutic, and CMC groups, respectively
(Fig. 1a, b). The preventative treatment group delayed the
onset of the first clinical sign of impairment (Fig. 1a, c).
The day of EAN onset was day 7.83 ± 0.17 in the preventa-
tive group, 6.33 ± 0.21 in the therapeutic group, and 6.00
± 0.26 in the CMC group (Fig. 1c). DMF also reduced the
AUC of the motor deficit assessed by clinical scoring
(Fig. 1d). Overall, both preventative and therapeutic DMF
treatment ameliorated EAN.
At the maximum of the clinical course of EAN (i.e., day
16 post-immunization), we evaluated the histopathology of
the rats’ sciatic nerves. H&E staining was used to show in-
flammatory cell infiltration, and LFB staining was used to
Fig. 1 DMF treatment attenuates the severity of EAN. EAN was induced in rats by immunization on day 0 with P0 peptide 180-199 (300 μg) emulsified in
complete Freund’s adjuvant and dissolved in vehicle. In a preventative treatment paradigm, DMF was administered from day 1 to day 27 (25 mg/kg, once
daily). By contrast, in a therapeutic treatment paradigm, DMF was administered from day 7 to day 27 at the same 25 mg/kg dose, once daily. In a control
condition, EAN rats received an equivalent volume of vehicle. Clinical scores (0–10, with 0 being normal to 10 being so severely impaired that the animals
died) were obtained daily post-immunization. a EAN clinical scores were significantly better in DMF-treated groups, but the pattern of im-
provement over time was different. The rats in the preventative treatment group exhibited significantly better clinical scores from day 6 to
day 27 compared with the rats in the CMC group (p< 0.05 on each time point). The rats in the therapeutic group had significantly better clinical scores
from day 10 to day 27 compared with the rats in the CMC group (p < 0.05 on each time point). b–d DMF reduced the peak score, the day of disease
onset, and the area under the curve (AUC) in EAN rats. On day 16 post-immunization, sciatic nerves of each group were harvested for H&E staining
(e) and LFB staining (g) to assess changes in infiltration and demyelination. Representative photomicrographs are shown for each group. The mean
number of inflammatory cells per square millimeter of tissue section was determined as described in the “Methods” section, and summaries are shown
in f. Mean histological scores are shown in h. Scores were calculated as described in the “Methods” section. Comparisons between the CMC
group and DMF-treated groups were performed using Mann–Whitney U tests. Arrows showed the inflammatory cells and the demyelination of
sciatic nerves. Scale bar in e and g is 10 μm. The results are presented as means ± SEM (*p < 0.05 for comparison between CMC and DMF-
treated groups, n = 6 per group). CMC vehicle control group, DMF-P preventative DMF group, DMF-T therapeutic DMF group. The experiment
was repeated 3 times with similar results
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show myelin demyelination. Treating EAN rats with DMF
in both treatment paradigms lowered the number of in-
flammatory cells (Fig. 1e, f). The incidence of demyelin-
ation and inflammatory cell infiltration was reduced by
DMF treatment in both paradigms (Fig. 1g, h). When the
stained tissue was semi-quantitatively graded, the mean
histological scores were markedly higher in the CMC group
(2.33 ± 0.25) compared to the scores of preventative (1.25 ±
0.17, p < 0.05) and therapeutic (1.33 ± 0.25, p < 0.05)
groups (Fig. 1h).
DMF protects against EAN-induced peripheral nerve injury
The ability of DMF to protect against EAN-induced per-
ipheral nerve injury was assessed by evoked response
electrophysiology at day 16 post-immunization in the
sciatic nerve. It is well known that EAN rats exhibit
decreasing CMAP amplitude and MNCV and lengthen-
ing of CMAP latency. In agreement with the clinical
findings shown in Fig. 1, DMF prevented the develop-
ment of peripheral nerve deficits in both DMF-treated
groups (Fig. 2). For the MNCV, the CMC group’s mean
conduction velocity was slower than the preventative
and therapeutic groups’ conduction velocity (37.73 ± 3.49
vs. 70.08 ± 8.25 m/s and 69.24 ± 11.73 m/s, p < 0.05,
Fig. 2c). For CMAP latency, the preventative group and
therapeutic group also showed a beneficial effect of DMF
on CMAP latency, which was shorter than the CMC
group’s average latency (0.29 ± 0.03 and 0.29 ± 0.04 ms vs.
0.55 ± 0.04 ms, p < 0.05, Fig. 2d). Also, the CMAP mean
amplitudes of the two DMF treatment groups were greater
(12.25 ± 2.52 and 17.72 ± 3.03 mV, respectively, Fig. 2e)
compared to the CMC group (10.25 ± 2.04 mV), but this
was not significant.
DMF promotes M2 macrophage polarization in EAN rats
and in vitro
To further investigate the mechanism of DMF’s beneficial
effect in EAN, we assessed possible DMF-related changes
in macrophage polarization in sciatic nerves and in spleens
of EAN rats. Double-immunohistochemical staining was
used to identify the proportion of M1 and M2 cells in sci-
atic nerves. Flow cytometry was also used to investigate
polarization state of MNCs derived from spleens of EAN
rats treated in the different DMF paradigms. In sciatic
nerves harvested on day 16 post-immunization, DMF-
preventative and DMF-therapeutic groups both displayed
elevated local expression of M2 macrophages and reduced
expression of M1 macrophages compared to the CMC
group (Fig. 3a–c, p < 0.05 and Additional file 1: Figure S1).
Flow cytometry results of spleen MNCs followed the same
Fig. 2 DMF protects against peripheral nerve conduction deficits in EAN rats. Representative electrophysiological recordings of motor nerve compound
muscle action potentials (CMAPs) evoked from stimulation of the fibular head (a) or ankle regions (b) of the sciatic nerve are shown for CMC, DMF-P, and
DMF-T rats, respectively, from left to right. c Compared to the CMC group, DMF-treated groups were protected from EAN-induced damages of mean
motor nerve conduction velocity (MNCV). d Compared to the CMC group, DMF-treated groups also exhibited better distal motor latencies of CMAPs.
e DMF treatment improved the amplitude of CMAPs when compared to CMC groups, while we observed a non-significant trend. Comparisons between
the CMC group and DMF-treated groups were performed using Mann–Whitney U tests. Data shown are the means ± SEM (*p < 0.05 for comparison be-
tween CMC and DMF-treated groups; n= 5–6). CMC vehicle control group, DMF-P preventative DMF group, DMF-T therapeutic DMF group. The experi-
ment was repeated 3 times with similar results
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group patterns of M1/M2 expression. Both the DMF-
preventative and DMF-therapeutic groups showed elevated
expression of M2 and reduced expression of M1 macro-
phages in EAN spleens compared to the CMC group
(Fig. 3d–f, p < 0.05).
As a third line of evidence, we assessed the in vitro
polarization shift of macrophages after DMF treatment
using the murine macrophage cell line, RAW 264.7. The
M1 macrophage phenotype was first induced by in vitro
LPS application (5 μg/ml) for 24 h. Various concentrations
of DMF (20, 50, and 100 μM) were then added to the cul-
ture, and the cells were incubated for another 24 h. As
shown in Fig. 4, in vitro DMF application reduced the ex-
pression of iNOS and increased the expression of Arg1
significantly (Fig. 4a–d, p < 0.05) detected by fluorescence
immunohistochemistry. DMF application also attenuated
iNOS and TNF-α mRNA expression and increased
Arg1 and IL-10 mRNA expression (Fig. 4e–h, p < 0.05).
These results suggested a shift in polarization from the
M1 to M2 phenotype. Therefore, we verified in vitro
that DMF can promote a shift to M2 polarization, and
together with our previous results, these results showed
that the shift can possibly be induced in vivo as well by
DMF treatment.
Fig. 3 DMF promotes M2 macrophage polarization in EAN. DMF was administered orally to EAN rats (n= 6 in each group) from day 1 to day 16 or day 7
to day 16 post-immunization for preventative or therapeutic treatment, respectively. On day 16 post-immunization, sciatic nerves of each group of rats
were harvested for fluorescence immunohistochemistry, and spleen mononuclear cells (MNCs) were isolated for flow cytometry, in both cases to analyze
the proportion of M1 macrophages and M2 macrophages in EAN after DMF treatment paradigms. a Fluorescence photomicrographs showing M1 and M2
macrophages in the sciatic nerves of EAN rats. Tissue sections were immunofluorescence stained for markers of M1 and M2 macrophages as indicated.
Scale bar is 50 μm. b Quantitation of immunohistochemistry. Counts per square millimeter of CD68+/CD86+ cells (M1 phenotype) in the sciatic nerve
showed that DMF reduced the number of M1 macrophages in both DMF treatment paradigms. c Counts per square millimeter of CD68+/CD206+ cells
(M2 phenotype) showed that DMF-treated groups increased the number of M2 macrophages in both DMF treatment paradigms compared to the CMC
group. d Flow cytometry results of spleen MNCs showed the same pattern of M1/M2 phenotype shift as a result of both DMF-preventative and DMF-
therapeutic treatment paradigms. e Quantitation of flow cytometry. Percentage of M1 phenotype in spleen MNCs was lower in both DMF-treated groups.
f Percentage of M2 macrophages in spleen MNCs was greater in both DMF-treated groups. Comparisons to CMC group were performed using the Mann–
Whitney U test; quantitation shows means ± SEM (*p< 0.05 for comparison between CMC and DMF-treated groups; n= 4–5). CMC control group receiving
vehicle, DMF-P preventative DMF treatment, DMF-T therapeutic DMF treatment. The experiment was repeated 3 times with similar results
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DMF increases Nrf2 and HO-1 protein levels in sciatic
nerves of EAN rats
Nrf2 protein regulates the expression of antioxidant
proteins that protect against oxidative damage related
to inflammation, and HO-1 is a key downstream medi-
ator of Nrf2. As M2 macrophages highly express HO-1
[22], we explored the effect of DMF on the level of
Nrf2 and HO-1. Sciatic nerves were taken from EAN
rats on post-immunization day 16 for fluorescence im-
munohistochemistry and Western blotting analysis to
study the cellular expression of Nrf2/HO-1. In sciatic
nerve tissue sections, DMF-preventative and DMF-
therapeutic groups showed robust localized cellular ex-
pression of Nrf2 and HO-1 compared to the CMC group
(Fig. 5a, b, d, p < 0.05). Furthermore, detection by Western
blotting also showed an increased level of Nrf2 and HO-1
(Fig. 5e–g, p < 0.05). In addition, co-staining macrophages
with Nrf2 showed that DMF-treated groups had a higher
radio of Nrf2-positive macrophages than CMC group
(Fig. 5a, c, p < 0.05).
DMF ameliorates lymphocyte proliferative responses and
alters cytokine profile
MNCs prepared from EAN rat spleens on day 16 post-
immunization were stimulated in vitro with P0 peptide
180-199 (10 μg/ml) or without peptide for 72 h to evaluate
the effect of DMF on lymphocyte-proliferative responses
(Fig. 6a). When compared to the CMC group, a significant
Fig. 4 DMF applied in vitro induces M2 macrophage polarization. The murine macrophage cell line RAW 264.7 was used to verify DMF’s effect on
phenotype shift. M1 macrophage phenotype was induced first by LPS (5 μg/ml) for 24 h, and then DMF (20, 50, or 100 μM) or vehicle was applied to
the culture and allowed to incubate for 24 h. In vitro application of DMF reduced the immunocytochemical staining of iNOS+ cells (a) and increased
the immunocytochemical staining of Arg1+ cells (b). The results were significant by semi-quantitative analysis of immunofluorescence for iNOS (c) and
Arg1 (d). DMF application significantly attenuated mRNA expression of iNOS (e) and TNF-α (f). mRNA expression of Arg 1 (g) and IL-10 (h) increased
significantly after DMF treatment. These results suggested a polarization shift from M1 to M2 phenotype. Scale bars in a and b are 50 μm. Comparisons
between the DMF-treated groups and DMF-untreated control group (PBS) were performed using the Mann–Whitney U test. Results are expressed as
means ± SEM (*p < 0.05 compared to the group stimulated with LPS only, n = 4)
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reduction in lymphocyte proliferation was observed in the
preventative group and therapeutic group (0.91 ± 0.08 vs.
0.58 ± 0.02, and 0.54 ± 0.05, respectively) (Fig. 6a, p <
0.05), as measured by MTS assay with P0 peptide stimula-
tion. The same pattern of lymphocyte proliferation was
observed without peptide stimulation, and there was no
significant difference between DMF treatment groups and
the control group (data not shown).
As is well documented, the expression profiles of cyto-
kines affect the outcome of EAN. Therefore, we semi-
Fig. 5 Preventative and therapeutic DMF treatment increases the production of Nrf2, the percentage of Nrf2 in macrophages, and the level of
HO-1 in sciatic nerves of EAN rats. DMF was administered orally to EAN rats (n = 6 in each group) from day 1 to day 16 and day 7 to day 16 post-
immunization for preventative and therapeutic treatment, respectively. On day 16 post-immunization, sciatic nerves of rats from each group were
harvested for fluorescence immunohistochemistry and Western blotting. DAPI counterstaining was used in tissue sections for cellular identification. a
Fluorescence photomicrographs of anti-Nrf2 (green), anti-CD68 (red), and anti-HO-1 (red) staining. In both the DMF-preventative and DMF-therapeutic
groups, Nrf2 and HO-1 stainings were more intense and robust when compared to the CMC group. Co-staining macrophages with Nrf2 showed that
DMF-treated groups had a higher radio of Nrf2 positive macrophages than CMC group. Scale bar is 20 μm. b Quantitation of cellular anti-Nrf2 staining.
There were significantly more Nrf2+ cells per square millimeter in the DMF-treated groups compared to the CMC group. c Fluorescence photomicrographs
and quantitation of anti-Nrf2 and anti-CD68 staining showed that in both the DMF-preventative and DMF-therapeutic groups, the percentage of Nrf2- and
CD68-positive cells in CD68-positive cells was higher when compared to the CMC group. d Quantitation of cellular anti-HO-1 staining. There was
significantly more HO-1+ cells in the DMF-treated groups compared to the CMC group. e Western blotting of Nrf2 and HO-1 protein compared to
β-actin standard. DMF-preventative and DMF-therapeutic groups both showed increased expression of Nrf2 and HO-1 in sciatic nerves when compared to
the CMC group. f, g Quantitation of Western blotting of Nrf2 and HO-1. Relative expression of Nrf2 and HO-1 in DMF-treated groups was significantly
greater compared to the CMC group. Comparisons between the CMC group and DMF-treated groups were made by Mann–Whitney U test. Results are
expressed as means ± SEM (*p< 0.05 compared to the CMC control group; n= 4–5). The experiment was repeated 3 times with similar results
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quantitatively analyzed the effects of DMF treatment on
the cytokine profiles produced in vitro by MNCs from
EAN rats in response to the presence of P0 peptide 180-
199 using multi-cytokine ELISA kits. As shown in
Fig. 6b, the production of pro-inflammatory cytokines
(IL-6, IFN-γ, IL-1α, and TNF-α) by MNCs cultured with
P0 peptide 180-199 (10 μg/ml) was reduced in both
DMF treatment groups compared to that in the CMC
group. While TNF-α, IL-6, and IFN-γ were all signifi-
cantly reduced (Fig. 6b, p < 0.05), the levels of IL-1α
were not reliably different from those in the CMC
group. By contrast, the levels of the anti-inflammatory
cytokines IL-4 and IL-10 were upregulated. However,
only levels of IL-4 were significantly greater compared
to the CMC group (Fig. 6b, p < 0.05); large variability in
IL-10 levels among the groups apparently reduced the
statistical power to detect a reliable difference.
We confirmed these changes in cytokine production in
DMF-treated MNCs by using RT-PCR of splenocyte sam-
ples. As shown in Fig. 6c–h, IFN-γ, TNF-α, IL-6, and IL-17
mRNA levels were greatly reduced in DMF-treated groups
compared to those in the CMC group (Fig. 6c–f, p < 0.05),
while IL-4 and IL-10 mRNA levels increased significantly
(Fig. 6g, h, p < 0.05).
Discussion
In the present study, DMF therapy suppressed the effects
of EAN, manifested overtly in a delay of clinical symptom
onset and in a reduction in the severity of paralysis. These
beneficial overt effects were associated with reduced in-
flammation and demyelination of the sciatic nerves. We
also observed a decrease in the often-damaging M1 macro-
phage phenotype and an increase in the M2 phenotype in
both sciatic nerves and spleens of DMF-treated rats and in
vitro. In addition, the level of Nrf2 and HO-1 increased sig-
nificantly in DMF-treated groups. Furthermore, DMF im-
proved the inflammatory environment by depressing the
level of pro-inflammatory cytokines and increasing the
level of anti-inflammatory cytokines.
Assessing neurological symptoms through clinical scores,
we observed that DMF greatly improved EAN symptoms
by reducing paralysis severity, delaying the onset of the first
signs of EAN, decreasing the peak clinical score, and redu-
cing motor deficits. EMG studies revealed that DMF
Fig. 6 DMF ameliorates lymphocyte proliferative responses and alters cytokine profiles. Splenic mononuclear cells (MNCs) from each group (n = 6)
were harvested on day 16 post-immunization. a MNCs proliferation following DMF treatment. After culturing MNCs for 72 h in the presence of P0 peptide
180-199 (10 μg/ml), MNC proliferation was analyzed by MTS assay. When compared to the CMC group, a significant reduction in proliferation was observed
in DMF-preventative and DMF-therapeutic groups. b Cytokine profiles of the supernatants of spleen MNCs cultured with P0 peptide 180-199 (10 μg/ml) for
72 h, as measured by ELISA. The levels of TNF-α, IL-6, and IFN-γ decreased greatly, but the level of IL-4 increased compared to the CMC group. A trend in
increasing IL-10 levels and decreasing IL-1α levels was evident but not statistically significant. c–h IL-6, IL-4, IL-10, IFN-γ, TNF-α, and IL-17 mRNA expression
levels in the splenocytes of EAN rats, as measured by RT-PCR. The level of pro-inflammatory cytokines IFN-γ, TNF-α, IL-6, and IL-17 decreased
in DMF-treated groups, while the level of anti-inflammatory cytokines IL-4 and IL-10 increased significantly. Each experiment was performed in
triplicate for each group. Comparisons between the CMC group and DMF-treated groups were performed using Mann–Whitney U tests. Data shown
are means ± SEM (*p < 0.05 for comparison between CMC and DMF-treated groups, n = 4). The experiment was repeated 3 times with similar results
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generally protected nerves from EAN-induced peripheral
nerve injury by improving MNCV and amplitudes of
CMAPs and by reducing the distal motor latency com-
pared to the CMC group. Histopathologically, EAN is
characterized by inflammatory cell infiltration and nerve
demyelination. In the present study, both preventative and
therapeutic DMF treatment significantly suppressed the
accumulation of inflammatory cell infiltration and demye-
lination when compared to the CMC group. Taken to-
gether, these results demonstrate that DMF had beneficial
effects in EAN rats.
Macrophages are broadly divided into two groups: clas-
sically activated (M1) and alternatively activated (M2) mac-
rophages [28]. M1-type macrophages release cytokines that
inhibit the proliferation of surrounding cells and damage
contiguous tissue, whereas M2-type macrophages release
cytokines that promote the proliferation of contiguous cells
and tissue repair [10]. Furthermore, alternatively activated
M2 macrophages play an immunomodulatory role in EAN
[29, 30], leading to a favorable outcome. Consistent with
the previous findings, the present study showed that the
ameliorated outcome of EAN rats was associated with the
polarization of macrophages toward the M2 phenotype.
There were many more M2-type and fewer M1-type mac-
rophages in the sciatic nerves of DMF-treated EAN rats.
Besides, flow cytometry results showed that splenic macro-
phages in DMF-treated EAN rats polarized toward the M2
type. This finding was also consistent with in vitro findings
showing that DMF application in the culture bath directly
affected macrophages differentiation. Indeed, treating LPS-
stimulated macrophages with DMF significantly reduced
mRNA expression of inflammatory molecules, such as
iNOS and TNF-α, and induced mRNA expression of anti-
inflammatory cytokines, such as IL-10. These data sup-
ported the idea that DMF improved the outcome of EAN
by promoting M2 type differentiation.
Based on previous mechanistic studies with cell cul-
ture models and MS, it was proposed that DMF’s thera-
peutic mechanism is mainly the activation of Nrf2 [19].
Evidences show that Nrf2 is beneficial for other auto-
immune and inflammatory diseases as well [31–35].
Corroborating these studies, our study revealed that in
EAN, DMF upregulated Nrf2 in vivo. It is reported that
Nrf2 exerts anti-inflammatory and anti-oxidation effects
through initiating the transcription of a range of down-
stream genes, mainly including NQO1 and HO-1 [36].
HO-1 participates in a critical protective mechanism that
is activated during cellular stress [37] and is regarded as an
adaptive cellular response against inflammatory responses
and oxidative injury [38]. In EAN, HO-1 is predominantly
expressed starting 11 days after immunization, with local
expression persisting long after neurologic signs disappear
[39]. Consistent with the findings from the previous study,
we observed that HO-1 expression is detectable during the
peak phase of spontaneous EAN. Furthermore, in DMF-
treated EAN rats, both the production of HO-1 and Nrf2
were much greater than that in the control group. Consid-
ering HO-1 induction can affect macrophage polarization
toward the M2 phenotype in vivo and ex vivo [22, 40], it is
reasonable to hypothesize that DMF induces macrophages
to polarize toward the M2 type by upregulating the level of
HO-1 and Nrf2. Therefore, we further explored the expres-
sion of Nrf2 in macrophages, and result showed that treat-
ing EAN rats with DMF can upregulate its expression in
macrophages. Besides, it was proposed that in mice and
humans, mechanisms underlying DMF’s protective effects
in inflammatory autoimmune diseases also involved the in-
hibition of Th1/Th17 cells and induction of Th2 cells [41].
The authors attributed the polarization of T cells to the
induction of HO-1 and thus the increased level of type II
dendritic cells [41]. Therefore, the effects seen in present
study on macrophages in vivo could also be secondary due
to dendritic cell-mediated immune regulation. Additional
in vitro investigations are needed to confirm the effects of
DMF on the expression of HO-1 in macrophages and to
clarify the role of HO-1 and dendritic cells in the
polarization of macrophages in EAN.
DMF has been demonstrated to reduce inflammation in
autoimmune and inflammatory animal models [23, 24, 33,
41–44]. In accordance with previous reports, the present
study showed that DMF reduced the inflammatory re-
sponse in EAN rats and favored the outcomes. DMF re-
duced the mRNA expression of IFN-γ, TNF-α, IL-6, and
IL-17 and upregulated the mRNA expression of IL-4 and
IL-10 in the spleens of EAN rats. In addition, the same
trend in cytokine profile was observed in the ELISA ana-
lysis of the supernatants of cultured spleen MNCs. These
data revealed that the improvement of inflammatory
environment by DMF was a basis for the protective effect
in EAN. Although these data were obtained from spleen
samples and may not exactly represent changes in periph-
eral nerves in situ, as they were obtained from animals
after in vivo administration of DMF, they may nonetheless
provide mechanistic insight into the physiological activities
underpinning this potentially valuable therapeutic and shed
light on the positive clinical outcome we observed.
Conclusions
We have demonstrated that DMF promotes EAN ameli-
oration through a Nrf2/HO-1-mediated phenotypic shift
in macrophages. The anti-inflammatory effects of DMF
also improve the environmental milieu in immune organ
and indirectly exert neuroprotective effects.
Additional file
Additional file 1: Figure S1. DMF promotes M2 macrophage polarization
in EAN. DMF was administered orally to EAN rats (n = 6 in each group) from
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day 1 to day 16 or day 7 to day 16 post-immunization for preventative
or therapeutic treatment, respectively. On day 16 post-immunization,
sciatic nerves of each group of rats were harvested for fluorescence
immunohistochemistry to analyze the proportion of M1 macrophages
and M2 macrophages in EAN rats after DMF treatment paradigms. (A)
Fluorescence photomicrographs showing M1 and M2 macrophages in
the sciatic nerves of EAN rats. Tissue sections were immunofluorescence
stained for markers iNOS of M1, Arg1 of M2 macrophages, and Iba1 of
general macrophages as indicated. Scale bar is 50 μm. (B) Quantitation
of immunohistochemistry. Counts per square millimeter of Iba1+/iNOS+
cells (M1 phenotype) in the sciatic nerve showed that DMF reduced the
number of M1 macrophages in both DMF treatment paradigms. (C) Counts
per square millimeter of Iba1+/Arg1+ cells (M2 phenotype) showed that
DMF-treated groups increased the number of M2 macrophages in both DMF
treatment paradigms compared to the CMC group (p < 0.05). (DOCX 399 kb)
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